[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urological-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urological-surgery":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100644606","pbm-patch-for-postoperative-pain-relief-after-urological-surgery-100644606",false,"NCT07671612","PBM Patch for Postoperative Pain Relief After Urological Surgery","A Double-blind Randomized Controlled Clinical Study of the PBM Patch for Postoperative Pain Relief After Urological Surgery","Inclusion Criteria:\n\n1. Patients aged 18 years or older undergoing unilateral nephroureterectomy with bladder cuff excision, or adrenalectomy (tumor size \\\u003C 3.5 cm).\n2. Patients who are capable of clear verbal communication.\n3. Patients who are able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Individuals with photosensitive constitution or those currently using photosensitizing medications.\n2. Individuals with a known history of severe allergy or contact dermatitis to medical adhesive patches or tapes.\n3. Patients with severe psychiatric illness or cognitive impairment.\n4. Long-term or high-dose opioid users.\n5. Patients utilizing a Patient-Controlled Analgesia (PCA) pump.\n6. Individuals with severe hepatic insufficiency or active liver disease.\n7. Vulnerable populations, individuals with restricted legal capacity, or those who are unable or unwilling to undergo clinical evaluations.","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a prospective, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy and safety of a photobiomodulation (PBM) patch (Super Vi PBM Patch - Soothing) and an enhanced PBM patch (Super Vi PBM Patch - Soothing EX), compared with a placebo patch, for postoperative pain relief following urological surgery, including nephroureterectomy with bladder cuff resection (NU+BCR) and adrenalectomy (ADRX).",[26,27,28,29,30],"Urological Surgery","Photobiomodulation (PBM)","Non-pharmacological Intervention","Double-blind Randomized Controlled Study","Postoperative Pain Relief",[30,27,26,29,28],"NOT_YET_RECRUITING","2026-06-25",{"date":35,"type":36},"2026-06-26","ACTUAL",{"date":38,"type":20},"2026-07-01",{"date":40,"type":20},"2028-03-31",{"name":42,"class":43},"National Taiwan University Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100600332","ed90-of-teglidine-for-suppressing-lma-insertion-response-in-the-elderly-100600332","NCT07096115","ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly","The 90% Effective Dose of Taiglididine for Inhibiting Laryngeal Mask Insertion Response in Elderly Patients","Inclusion Criteria:\n\n1. Aged 65-80 years old.\n2. ASA physical status I-III.\n3. BMI 18-30 kg\u002Fm² (inclusive of critical values).\n4. Mallampati class I or II, mouth opening \\>2.5 cm.\n5. No abnormal airway or head\u002Fneck conditions.\n6. No risk of reflux or aspiration (e.g., full stomach, obesity, gastrointestinal obstruction).\n7. Expected surgery duration \\\u003C180 min.\n8. Scheduled for urological surgery requiring general anesthesia and laryngeal mask insertion.\n9. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\nBaseline measurements: Severe hypertension (SBP \\>160 mmHg or DBP \\>100 mmHg), heart rate \\\u003C60 bpm or \\>100 bpm.\n\n2\\. History of long-term alcohol, sedative, or analgesic use; allergy to any study drugs.\n\n3\\. Severe dysfunction of vital organs (heart, lung, liver, kidney, nervous system), neuromuscular diseases, hyperthyroidism, obstructive sleep apnea syndrome.\n\n4\\. History of mental disorders or cognitive impairment severe enough to hinder understanding or cooperation with the study.\n\n5\\. Preoperative administration of sedative-hypnotics (including benzodiazepines and barbiturates).\n\n6\\. Upper respiratory tract infection within 1 month before surgery. 7. Participation in other clinical studies within the past 3 months. 8. Other conditions deemed unsuitable for the trial by the investigator.",true,"65 Years","80 Years",{"count":55,"type":20},45,[23],"This research protocol aims to investigate the 90% effective dose (ED90) of taiglididine for inhibiting laryngeal mask insertion response in elderly patients. It is a non-randomized controlled trial using a biased coin design up-down method (BCD-UDM). A total of 54 elderly patients aged 65-80 years with ASA I-III, BMI 18-30 kg\u002Fm², and suitable for urological surgery under general anesthesia with laryngeal mask insertion will be enrolled. The first patient receives an intravenous injection of 1 mg taiglididine, followed by propofol and rocuronium. Subsequent doses of taiglididine are adjusted dynamically based on the previous patient's response: increasing by 0.1 mg if the insertion response is positive, or using BCD-UDM (11% probability to decrease by 0.1 mg, 89% to remain) if negative. The primary efficacy endpoint is the occurrence of laryngeal mask insertion response, while secondary endpoints include adverse events, vital sign changes, insertion success rate, and various time intervals. Safety is evaluated by monitoring vital signs. Statistical analysis will use SPSS 25.0 and R software to calculate ED90 and 95% confidence intervals via probit regression and bootstrap method, with at least 45 valid patients required to complete the trial.",[26],[60,61],"Taiglididine","Elderly Patients","2025-07-24",{"date":64,"type":36},"2025-07-31",{"date":66,"type":20},"2025-09-01",{"date":68,"type":20},"2027-06-30",{"name":70,"class":43},"The First People's Hospital of Lianyungang"]